Mohamed Abdou Mohamed Salem
Dept. Head
Usefulness and Safety of Percutaneous Myocardial Laser Revascularization for Refractory Angina Pectoris
• 2004
Publication Information
Authors
Mohammed Salem, MD, Svein Rotevatn, MD, PhD, Sindre Stavnes, MD,
Magne Brekke, MD, Stein Emil Vollset, MD, DrPH, and Jan Erik Nordrehaug, MD, PhD
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
This prospective, double-blind, randomized, sham-controlled
trial was designed to control for patient and
investigator bias in assessing symptomatic improvement
after percutaneous myocardial laser revascularization
(PMLR) therapy. Eighty-two patients with stable angina
pectoris (class III or IV) not amenable to conventional
revascularization and with evidence of reversible ischemia,
ejection fraction >25%, and myocardial wall
thickness >8 mm were randomized to either PMLR with
optimal medical therapy (n 40) or to a sham procedure
with optimal medical therapy (n 42). With the
exception of 1 laser technician, all patients, investigators,
and assessors were blinded to treatment through
the 12-month follow-up. The primary end point was
restricted to Canadian Cardiovascular Society angina
class improvement to limit the number of patients exposed
to a sham procedure. Secondary assessments
included medication usage, quality of life, exercise testing,
ejection fraction, and hospitalizations. The incidence
of serious adverse events, as determined by cardiac
event-free survival at 12 months, was similar between
groups. At 12 months, Canadian Cardiovascular Society
angina scores improved by >2 classes in significantly
more PMLR-treated patients than sham control patients
(35% vs 14%, p 0.04). Angina-specific quality-of-life
measures were significantly higher in the PMLR group at
each follow-up (p
trial was designed to control for patient and
investigator bias in assessing symptomatic improvement
after percutaneous myocardial laser revascularization
(PMLR) therapy. Eighty-two patients with stable angina
pectoris (class III or IV) not amenable to conventional
revascularization and with evidence of reversible ischemia,
ejection fraction >25%, and myocardial wall
thickness >8 mm were randomized to either PMLR with
optimal medical therapy (n 40) or to a sham procedure
with optimal medical therapy (n 42). With the
exception of 1 laser technician, all patients, investigators,
and assessors were blinded to treatment through
the 12-month follow-up. The primary end point was
restricted to Canadian Cardiovascular Society angina
class improvement to limit the number of patients exposed
to a sham procedure. Secondary assessments
included medication usage, quality of life, exercise testing,
ejection fraction, and hospitalizations. The incidence
of serious adverse events, as determined by cardiac
event-free survival at 12 months, was similar between
groups. At 12 months, Canadian Cardiovascular Society
angina scores improved by >2 classes in significantly
more PMLR-treated patients than sham control patients
(35% vs 14%, p 0.04). Angina-specific quality-of-life
measures were significantly higher in the PMLR group at
each follow-up (p